Genzyme and Isis Announce Submission of European Marketing Authorization Application for Mipomersen (Kynamro)
Submission Seeks Approval for Mipomersen’s Use in the Treatment of Homozygous Familial Hypercholesterolemia and Severe Heterozygous Familial Hypercholesterolemia
01-Aug-2011 -
Genzyme, a Sanofi company, and Isis Pharmaceuticals Inc. announced that Genzyme has submitted a marketing authorization application (MAA) to the European Medicines Agency seeking approval for the 200 mg weekly dose of mipomersen for the treatment of homozygous and severe heterozygous familial ...
Genzyme
heterozygous familial hypercholesterolemia
homozygous familial hypercholesterolemia